Therapeutic potential of saroglitazar in dyslipidemia management

Summaries 1 min 291

Font Size

Created On: 01/11/2025

This systematic review and meta-analysis explored the effectiveness and safety profile of saroglitazar (antidiabetic medication) in patients suffering from dyslipidemia.

See All

Key take away

Saroglitazar significantly lowers LDL and total cholesterol levels while maintaining a favorable safety profile, showing no significant impact on liver enzymes, kidney function, or body weight.

Background

This systematic review and meta-analysis explored the effectiveness and safety profile of saroglitazar (antidiabetic medication) in patients suffering from dyslipidemia.

Method

A comprehensive search was carried out across Google Scholar, PubMed, Cochrane Library, and Scopus. Interventional studies evaluating the lipid-lowering efficacy and safety of saroglitazar, with or without comparator groups, were included. Effectiveness was measured by alteration in total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), non-HDL cholesterol, and fasting plasma glucose.

Safety outcomes encompassed monitoring serum creatinine, body weight changes, and liver enzymes—alanine aminotransferase (ALT) and aspartate aminotransferase (AST). With the help of the Cochrane risk of bias tool, the methodological quality of literature was examined.

Result

In total, 6 studies encompassing 581 adults (mean ages ranging from 40.2 to 62.6 years) were analyzed. Treatment with 4 mg saroglitazar resulted in a significant reduction in LDL cholesterol compared to the 2 mg dose [standardized mean difference (SMD): −0.23 mg/dL; 2 studies] and controls [SMD: −0.36 mg/dL; 3 studies].

Additionally, total cholesterol markedly dropped with the 4 mg dose when compared to 2 mg [SMD: −0.28 mg/dL; 2 studies] and control groups [SMD: −0.49 mg/dL; 3 studies]. No significant adverse effects related to serum creatinine, ALT, AST, or body weight were witnessed with saroglitazar usage.

Conclusion

Saroglitazar portrayed promising efficacy and safety as a treatment for dyslipidemia. Nonetheless, further comparative research involving other lipid-lowering agents is needed to validate these outcomes.